SR-BI, Rat, mAb 3D12
Monoclonal antibody 3D12 reacts with rat class B scavenger receptor type I (SR-BI). Scavenger receptors have been studied primarily for their ability to bind and internalize modified lipoproteins. They have been found in the development of atherosclerosis and other macrophage-associated functions. Scavenger receptors also function as pattern recognition receptors for a wide variety of pathogens. This finding indicates a potential role in host defense. SR-BI belongs together with CD36 to the class B scavenger receptor family. SR-BI is a multiligand membrane protein existing in various organs such as the liver and various cell types such as endothelial cells, macrophages, brain cells, Leydig cells and Sertoli cells. SR-BI has been found as a receptor for phospholipids, free and (lipo)protein-bound ApoE, lipid-bound ApoA-I, HDL, hypochlorite-modified LDL and more. In liver, the PDZK-1 (and possible other PDZ domains) of SR-BI has been found to be essential for cell surface expression and, hence, reverse cholesterol transport. In the brain, the presence of SR-BI seems to be involved in the uptake of oxidatively modified lipoproteins and beta-amyloid protein complexed with ApoE, suggesting SR-BI to be an important tool for studies on neurodegenerative disorders. In the testis, SR-BI is expressed in two somatic cell types: Leydig cells and Sertoli cells. SR-BI functions at least partly as a phosphatidyl serine receptor (PSR), enabling Sertoli cells to recognize and phagocytose apoptotic spermatogenic cells at all stages of differentiation. Monoclonal antibody 3D12 blocks the biological activity of rat SR-BI. For example, it inhibits the ability of SR-BI to mediate the corporation of lipids of HDL by SR-BI expressing cells.
Calculate your ELISA data easily
With the ELISA calculator you can easily calculate ELISA data. Assayfit Pro helps to perform curve fitting. The calculator generates advanced reports, fit graph, fit parameters and goodness of fit are shown.
Latest Hycult Biotech news
- New Human Complement Pathway AssaysWe are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to address the issue of false negative results, enabling more accurate and reliable analysis of complement… Read more: New Human Complement Pathway Assays
- Navigating the pitfalls in complement analysisOur colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not only the correct technique is used but also that pre-analytical sample handling is performed in… Read more: Navigating the pitfalls in complement analysis
- NEW Human C3d ELISAWe are happy to introduce our new ELISA (cat.# HK3017) designed to detect human C3d. What sets this assay apart is its utilization of a distinctive neo-epitope capture antibody that selectively targets a specific C3d region of the alpha chain, which is not available in other C3 variants. This way it specifically distinguishes C3d from native C3… Read more: NEW Human C3d ELISA